Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Eribulin Mesylate with Trastuzumab in HER2+ Breast Cancer
NCT01269346Phase 2Completed
- Sponsor
- Eisai Co., Ltd.
- Start
- Dec 2010
- Primary completion
- Mar 2013
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of eribulin in breast cancer, sponsored by Eisai Co., Ltd.. Started Dec 2010; status: completed.
02
Drugs
eribulin
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT01269346.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01269346.